IVF
Conditions
Keywords
natural cycle, hormone replacement cycle, gestational hypertensive disease, frozen cycle
Brief summary
Recent sutdies indicate that the existence of corpus lutein in the ovary is a key point to prevent preeclampsia, and patients undergoing FET with hormone replaced cycle have no corpus lutein and the absence of corpus lutein significantly increases the risk of preeclampsia in these patients. We aim to conduct a single center randomized controlled non-inferiority trial to compare the live birth rate and gestational hypertention disease rate between the natural cycle and the hormone replaced cycle in women undergoing FET.
Detailed description
Recent sutdies indicate that the existence of corpus lutein in the ovary is a key point to prevent preeclampsia, and patients undergoing FET with hormone replaced cycle have no corpus lutein and the absence of corpus lutein significantly increases the risk of preeclampsia in these patients. We aim to conduct a single center randomized controlled non-inferiority trial to compare the live birth rate and gestational hypertention disease rate between the natural cycle and the hormone replaced cycle in women undergoing FET. The investigators plan to enroll women scheduled for frozen-thawed cycles. Eligible participants will be randomised 1:1 to the natural cycle and the hormone replaced cycle for endometrium preparation. All other IVF procedures will be carried out following a routine method in each center. Women will be followed up until six months after randomisation for those who fail to get pregnant after the completion of the first embryo transfer or delivery for those who get pregnant after the embryo transfer. The primary outcome is live birth after the embryo transfer. Primary analysis will be by intention-to-treat analysis. A 10% live birth is considered to be valid. Considering 10% loss to follow-up with a significance level at 0.05 and a power of 80%, the investigators plan to recruit 960 women to demonstrate women treated with natural cycle have no inferiority regarding live birth rate than those treated with hormone replacement cycle.
Interventions
PROCEDUREnatural cycle for endometrium preparation
patients will not use oral contraceptive drugs
PROCEDUREhormone replaced cycle for endometrium preparation
patients will receive oral contraceptive drugs for menstruation before embryo transfer
Sponsors
Women's Hospital School Of Medicine Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
1. 20 to 45 years old women; 2. Scheduled to undergo frozen-thawed embryo transfer. 3. Agreeing with the informed consent.
Exclusion criteria
1. Hypertention disease before embryo transfer; 2. Oocyte or sperm donated cycles 3. Recurrent miscarriage (at least two miscarriage history) 4. Ovulatory dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Gestational hypertension rate | delivery | defined with blood pressure over 140/90 mmhg from gestational week 20 to delivery with or without other complications by the enrolled patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The pre-eclampsia rate | From gestational week 20 to delivery | Preeclampsia is defined using the current American College of Obstetricians and Gynecologists definitions (Gynecologists; and Pregnancy 2013) |
Contacts
PRINCIPAL_INVESTIGATORDan Zhang, M.D. Ph.D.
Women's Hospital School Of Medicine Zhejiang University
Outcome results
None listed